Ann Pharmacol Pharm | Volume 10, Issue 1 | Research Article | Open Access
Ahmed M, Ansari K, Mustafa G, Kumar V, Pandian R, Ahmed Z and Shukla SK
Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, J&K, India
Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India
#Equal Contribution
*Correspondance to: sanket shukla
Fulltext PDFPatients with Inflammatory Bowel Disease (IBD) and Type 2 Diabetes Mellitus (T2DM) are very critical illness. Since both conditions are linked with dysbiosis, therefore it is possible that inappropriate antibiotic therapy in the T2DM condition would increase the risk of IBD. With these concerns in mind, there is a clear incentive to promote narrow-spectrum antibiotics when treating both diseases together. The current study evaluated the effect of fidaxomicin, a new class of macrocyclic antibiotics, as a therapeutic approach for IBD treatment in the T2DM mice model. To achieve this goal, we first established a High-Fat Diet (HFD) induced T2DM mice model with IBD. We observed that the induction of IBD in HFD-fed mice increased susceptibility to the inflammatory environment as compared to controls. IBD induction also shortened the colon length in HFD mice when compared to Normal-Fed Mice (NFD). The overall Disease Activity Index (DAI) score was also found to be significantly higher in the HFD + DSS group of mice. Fidaxomicin treatment significantly improved the symptoms of colitis in HFD mice. The treatment further attenuated pro-inflammatory cytokine production and other physiological parameters like blood glucose and cholesterol levels. In addition, histological examinations and histological scores showed that fidaxomicin prevented colon damage in acute DSS-induced colitis in HFD mice. Moreover, fidaxomicin reshaped the gut microbiome in HFD colitis mice by increasing the relative abundance of the Firmicutes and Lactobacillus sp. In conclusion, we observed that T2DM enhanced the IBD severity, that prevented by fidaxomicin.
IBD (Inflammatory Bowel Disease); DSS (Dextran Sulfate Sodium); Gut microbiome; T2DM (Type 2 Diabetes Mellitus); HFD (High Fat Diet); NFD (Normal Feed Diet)
Ahmed M, Ansari K, Mustafa G, Kumar V, Pandian R, Ahmed Z, et al. Fidaxomicin Ameliorates Dextran Sulfate Sodium-Induced Colitis in Type 2 Diabetes Mice Model. Ann Pharmacol Pharm. 2026; 10(1): 1214..